Relaxin-2, pathophysiological insights and outcomes in heart failure with preserved ejection fraction: Findings from the NETDiamond cohort-Reference-Cited by-同舟云学术

Relaxin-2, pathophysiological insights and outcomes in heart failure with preserved ejection fraction: Findings from the NETDiamond cohort

Published:2022-10 Issue: Volume:365 Page:87-90
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Pintalhão Mariana,Vasques-Nóvoa Francisco,Couto-Viana Benedita,Pimentel Maria João,Neves João Sérgio,Mendonça Luís,Saraiva Francisca,Lourenço André P.,Ferreira Guilherme,Macedo Filipe,Araújo José Paulo,von Hafe Pedro,Almeida Jorge,Ferreira João Pedro,Castro-Chaves Paulo,Leite-Moreira Adelino

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference14 articles.

1. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review;van Riet;Eur. J. Heart Fail.,2016

2. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment;Borlaug;Eur. Heart J.,2011

3. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the heart failure association (HFA) of the European Society of Cardiology (ESC);Pieske;Eur. J. Heart Fail.,2020

4. Relaxin and the cardiovascular system: from basic science to clinical practice;Martins;Curr. Mol. Med.,2020

5. Relaxin-2 for heart failure with preserved ejection fraction (HFpEF): rationale for future clinical trials;Dschietzig;Mol. Cell. Endocrinol.,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic association of circulating relaxin-2 in acute heart failure;International Journal of Cardiology;2024-10

2. Polymorphisms and haplotypes of TOLLIP and MUC5B are associated with susceptibility and survival in patients with fibrotic hypersensitivity pneumonitis;Pulmonology;2024-02

3. Relaxin as a biological marker and therapeutic target in heart failure;Medical Journal of the Russian Federation;2023-11-08